Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 15/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20679617 | 0.89 | ENPP1 (0.74) | ENPP1LMNANPSR1MEN1MAPT | |
| SCHEMBL30675617 | 0.89 | ENPP1 (0.74) | ENPP1LMNANPSR1MEN1MAPT | |
| SCHEMBL21663584 | 0.87 | ENPP1 (0.64) | ENPP1 | |
| SCHEMBL21663413 | 0.84 | ENPP1 (0.70) | ENPP1LMNANPSR1MEN1MAPT | |
| SCHEMBL21663415 | 0.84 | ENPP1 (0.70) | ENPP1LMNANPSR1MEN1MAPT | |
| SCHEMBL20679534 | 0.80 | ENPP1 (0.85) | ENPP1LMNANPSR1 | |
| SCHEMBL30675624 | 0.80 | ENPP1 (0.85) | ENPP1LMNANPSR1 | |
| SCHEMBL20679569 | 0.79 | ENPP1 (0.88) | ENPP1LMNANPSR1MEN1MAPT | |
| SCHEMBL30675561 | 0.79 | ENPP1 (0.88) | ENPP1LMNANPSR1MEN1MAPT | |
| SCHEMBL20679592 | 0.76 | ENPP1 (0.75) | ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020028724-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2020-02-06 | — | — | WO | disclosed |